Company Filing History:
2 out of 9 
1 out of 132 
1 out of 1 Years Active: 2019
Title: Naohiko Anzai: Innovator in Anticancer and Gout Treatments
Introduction
Naohiko Anzai is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the fields of medicine and pharmacology, particularly in the development of treatments for cancer and gout. With a total of 2 patents, Anzai's work reflects his dedication to advancing healthcare solutions.
Latest Patents
Anzai's latest patents include an anticancer agent composition and a URAT1 inhibitor. The anticancer agent composition involves a method for treating cancer by administering a combination of active ingredients, including a LAT1 inhibitor and various other agents such as alkylating agents and platinum-based antineoplastic agents. The URAT1 inhibitor patent describes a compound used as a therapeutic agent for gout or hyperuricemia, showcasing his innovative approach to addressing complex medical conditions.
Career Highlights
Throughout his career, Anzai has worked with notable companies such as J-Pharma Co., Ltd. and Nippon Chemiphar Co., Ltd. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research and development.
Collaborations
Some of Anzai's coworkers include Hitoshi Endou and Michael Fitzpatrick Wempe. Their collaborative efforts have likely played a role in the success of his inventions and patents.
Conclusion
Naohiko Anzai's contributions to medical innovation, particularly in cancer and gout treatments, highlight his role as a significant inventor in the pharmaceutical industry. His patents reflect a commitment to improving patient outcomes through advanced therapeutic solutions.